Two drugs and one poison can destroy the optic nerve in ways that are partly preventable if caught early: ethambutol, a first-line tuberculosis drug, and methanol, the alcohol found in improperly distilled spirits and some industrial solvents. Both cause damage to retinal ganglion cells, the neurons whose axons form the optic nerve. Citicoline has a real research history in protecting those exact cells, which is why it turns up in searches about both. The evidence connecting it to these two specific poisonings is worth looking at directly, because it is smaller than it sounds and the dosing is the part nobody quotes.
Nothing here constitutes medical advice. Citicoline has not been approved by the FDA to diagnose, treat, cure, or prevent optic neuropathy or any other condition. Suspected methanol poisoning is a medical emergency requiring immediate hospital treatment, and vision changes while taking ethambutol require urgent contact with the prescribing clinician.
Key Takeaways
- The entire evidence base for citicoline in ethambutol and methanol optic neuropathy is two rat studies. There are no human trials [1][2].
- Both used 1 gram of citicoline per kilogram of body weight per day. Scaled to a 70 kg adult by standard species conversion, that is roughly 11 grams a day, more than twenty times a common 500 mg capsule [1][2].
- The two studies used 15 rats each. The methanol study split its 15 animals across five groups, meaning three rats per group [2].
- In both, citicoline was given at the same time as the toxin, not after damage appeared. That is a prevention design, and real patients present after vision has already changed [1][2].
- The methanol study found no difference in photoreceptors between treated and untreated animals; the effect was confined to ganglion cells [2].
- The correct response to ethambutol vision changes is prompt medical review of the drug, and to methanol exposure is emergency care. Neither is a supplement decision.
What These Two Conditions Are
Ethambutol optic neuropathy is a recognized and dose-dependent side effect of a drug that remains standard in tuberculosis treatment. It typically presents with gradual painless loss of visual acuity and impaired color vision, often affecting both eyes. Its established management is not pharmacological rescue; it is recognizing it early and having the prescriber reassess the drug, because damage caught early is more likely to be reversible.
Methanol toxicity is a different clinical situation entirely. Methanol itself is relatively inert, but the body metabolizes it into formic acid, which poisons mitochondrial function and is directly toxic to the optic nerve and retina. It causes metabolic acidosis and can cause permanent blindness or death. Treatment is time-critical hospital care with an antidote that blocks that metabolism, plus supportive management and often dialysis. Nothing on a supplement shelf is relevant to that window.
Both share a final common pathway: retinal ganglion cell death. That is the connection citicoline is reaching for, and it is a legitimate one. Citicoline’s most developed clinical evidence is in glaucoma, which is also a retinal ganglion cell disease, covered in our article on citicoline and glaucoma. The mechanism is described in more depth in our neuroprotection overview.
The Ethambutol Study
Published in the Journal of Ocular Pharmacology and Therapeutics in 2022, this study used 15 Wistar rats divided into three groups: no treatment, ethambutol at 35 mg/kg/day, and ethambutol plus citicoline at 1 g/kg/day. Both treated groups received their compounds orally for 30 days, after which the retinas were examined by histopathology for ganglion cell density and by immunohistochemistry for bcl-2, an anti-apoptotic protein, and caspase-3, a pro-apoptotic one [1].
Ganglion cell density was significantly higher in the citicoline-treated animals than in those given ethambutol alone, with p less than 0.001. Citicoline-treated retinas showed higher bcl-2 expression and lower caspase-3 expression, a pattern consistent with reduced programmed cell death [1].
One finding in that paper is easy to misread. The ganglion cell layer was thicker in the animals that did not receive citicoline. Thicker sounds better, and here it is worse: the authors attribute the increased thickness to vacuole formation in the cytoplasm of the ganglion cells, which is a sign of cellular injury and swelling rather than of healthy tissue [1]. Structural measurements need their direction interpreted, not assumed.
The Methanol Study
From the same journal in 2021, this study used 15 Sprague-Dawley rats across five groups: a control group, methanol groups observed at day 3 and day 7, and methanol-plus-citicoline groups at the same two time points. Animals were placed in an inhalation chamber and given methanol orally; the treatment groups received citicoline at 1 g/kg every 24 hours by mouth. Retinas were assessed for photoreceptor morphology, ganglion cell density, and the same bcl-2 and caspase-3 markers [2].
Ganglion cell density was higher in citicoline-treated intoxicated rats at both day 3 and day 7, each with p less than 0.001. The ganglion layer was thinner in treated animals, interpreted here as milder swelling. Treated rats showed higher bcl-2 and lower caspase-3 [2].
Two details deserve attention. No differences were found in photoreceptor findings among the groups, so whatever protection occurred was specific to ganglion cells rather than general retinal rescue. And 15 animals divided into five groups leaves three per group. Statistical significance is achievable at that size when an effect is large, but three animals per arm is at the very bottom of what a preclinical study can be built on, and the authors themselves conclude that more preclinical and clinical trials are needed to establish a preferred dose and timing [2].
The Dose Is the Part That Does Not Transfer
Both studies used 1 gram of citicoline per kilogram of body weight per day. Animal doses do not convert to human doses one-for-one, because smaller animals have faster metabolic rates relative to body mass. The standard approach is body surface area scaling, which for rat-to-human conversion divides the rat dose by roughly 6.
Applying that, 1,000 mg/kg in a rat corresponds to something on the order of 160 mg/kg in a human. For a 70 kg adult that is approximately 11 grams of citicoline per day.
Set that against the real world. Common citicoline supplements are 250 mg or 500 mg per capsule, and the clinical trials in stroke and cognition generally use 500 to 2,000 mg per day. Our dosage guide covers the ranges that have actually been studied in people. The rat protective dose is roughly five to twenty times the highest routinely used human dose, and more than twenty times a typical single capsule.
This is the point on which the whole article turns. Even if the rat findings translated perfectly across species, which is a large assumption on its own, nobody is taking the dose that produced them. A 500 mg capsule is not a smaller version of the intervention that was tested. It is a different intervention.
Timing Is the Second Problem
In both studies, citicoline was administered concurrently with the toxin, from the start. The ethambutol animals received both compounds together across the same 30 days. The methanol animals received citicoline every 24 hours from the point of exposure [1][2].
That models prophylaxis. A person taking ethambutol for tuberculosis who notices their color vision fading is not in a prophylaxis scenario; the damage is underway. Someone who has drunk contaminated spirits is further still from it. Whether a neuroprotective compound helps before an insult and whether it helps after are separate empirical questions, and only the first one was asked here.
It is worth noting that this same timing distinction has produced opposite results elsewhere in the citicoline literature. In at least one animal seizure model, citicoline given after the event was associated with worse outcomes than vehicle, not better. Assuming that a compound that protects in advance will also rescue afterward is not a safe assumption.
Where the Broader Ophthalmic Literature Sits
Citicoline does have a serious presence in ophthalmology, and comprehensive reviews of citicoline in ophthalmological neurodegenerative disease treat glaucoma, anterior ischemic optic neuropathy, and diabetic retinopathy as the areas with meaningful clinical data, spanning psychophysical, electrophysiological, and morphological outcomes [3]. Reviews of citicoline in retinal pathology take a similar view, positioning it as a neuroprotective candidate in conditions where existing treatments fail to halt progression [4].
What is telling is that toxic optic neuropathy from ethambutol or methanol does not feature in those reviews as an established application. It is a hypothesis at the preclinical stage, in a field where citicoline already has better-supported uses.
The Practical Answer
If you are on ethambutol and your vision or color perception changes, contact the prescribing clinician promptly. Ethambutol optic neuropathy is dose- and duration-related, and the decision that affects the outcome is about the drug regimen, made by the person managing the tuberculosis treatment. Adding a supplement is not a reason to delay that call, and continuing a drug that is damaging the optic nerve because a supplement is supposedly protecting it would be a serious mistake.
If methanol exposure is suspected, that is an emergency. Go to hospital. There is a specific antidote and a narrow window, and nothing described in this article is part of that treatment.
If the underlying question is whether citicoline supports optic nerve health generally, that is a fairer question with better evidence behind it, and the glaucoma literature is the place to look rather than these two rat studies. What the ethambutol and methanol work supports is a research direction. It does not support a purchase, and at the doses actually sold it does not correspond to what was tested.
Frequently Asked Questions
Does citicoline protect against ethambutol eye damage?
Only one study has examined this, in 15 rats. Citicoline-treated animals had higher retinal ganglion cell density and a more favorable pattern of cell-death markers than animals given ethambutol alone. There are no human trials, and the dose used scales to roughly 11 grams a day for an adult.
Can citicoline help after methanol poisoning?
Methanol poisoning is a medical emergency treated with a specific antidote and often dialysis, and citicoline plays no role in that care. One rat study reported preserved ganglion cell density with citicoline, but it used three animals per group, gave citicoline from the moment of exposure, and found no effect on photoreceptors.
How much citicoline did the rat studies use?
Both used 1 gram per kilogram of body weight per day. Using standard body surface area scaling, that corresponds to roughly 160 mg/kg in a human, or about 11 grams a day for a 70 kg adult. Typical supplements are 250 to 500 mg per capsule, and human trials generally use 500 to 2,000 mg per day.
Should I keep taking ethambutol if I take citicoline?
That decision belongs entirely to the clinician managing the tuberculosis treatment. Ethambutol optic neuropathy is dose- and duration-dependent, and early recognition with prompt medical review is what protects vision. No supplement changes that, and treating one as protection while continuing a drug that is causing damage would be dangerous.
Why does the timing of the animal studies matter?
Because citicoline was given at the same time as the toxin in both studies, which tests prevention rather than treatment. People seek help after vision has already changed. Whether a compound protects beforehand and whether it rescues afterward are different questions, and elsewhere in the citicoline literature after-the-fact dosing has produced worse outcomes in an animal seizure model.
Is there better evidence for citicoline and eye health?
Yes, in glaucoma and some other optic nerve conditions, where the clinical literature includes human studies with psychophysical, electrophysiological, and structural outcomes. Toxic optic neuropathy from ethambutol or methanol is not among the established applications in ophthalmology reviews.
References
- Nusanti S, Andalusia R, Adisti I, Sidik M. The Effect of Citicoline on Ethambutol Optic Neuropathy: Histopathology and Immunohistochemistry Analysis of Retina Ganglion Cell Damage Level in Rat Model. J Ocul Pharmacol Ther (2022). PMID 36074092
- Laksmita YA, Sidik M, Siregar NC, Nusanti S. Neuroprotective Effects of Citicoline on Methanol-Intoxicated Retina Model in Rats. J Ocul Pharmacol Ther (2021). PMID 34495749
- Oddone F, Rossetti L, Parravano M, Sbardella D, Coletta M, Ziccardi L, Roberti G, Carnevale C, Romano D, Manni G, Parisi V. Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review. Pharmaceuticals (Basel) (2021). PMID 33804675
- Nieves-Moreno M, Noval S, Pena-Garcia P, et al. The Role of Citicoline and Coenzyme Q10 in Retinal Pathology. Int J Mol Sci (2023). PMID 36982157
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
